A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Clinical trial NCT03546894 · COMPLETED

Trial details

NCT number: NCT03546894
Sponsor: Takeda
Status: COMPLETED
Study type: OBSERVATIONAL

Anaplastic Lymphoma Kinase-positive Carcinoma Non-small-cell Lung

Start date: 2018-07-23
Primary completion: 2023-02-13
Enrollment: 111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.